Immune cell topography of head and neck cancer
Background Approximately 50% of head and neck squamous cell carcinomas (HNSCC) recur after treatment with curative intent. Immune checkpoint inhibitors are treatment options for recurrent/metastatic HNSCC; however, less than 20% of patients respond. To increase this response rate, it is fundamental...
Saved in:
| Main Authors: | Bernard A Fox, Rieneke van de Ven, Carmen Ballesteros-Merino, Tara Muijlwijk, Sonja H Ganzevles, Ruud H Brakenhoff, Jos B Poell, Dennis N L M Nijenhuis, C René Leemans, Laura A N Peferoen, Elisabeth Bloemena, Fatima Ekhlas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/7/e009550.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Author Correction: Hallmarks of a genomically distinct subclass of head and neck cancer
by: Tara Muijlwijk, et al.
Published: (2025-02-01) -
No Evidence for FANCF Gene Silencing in Head-and-Neck Squamous Cell Carcinomas
by: Najim Ameziane, et al.
Published: (2009-01-01) -
Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer
by: Tanja D de Gruijl, et al.
Published: (2024-07-01) -
Commentary on differential impact of TIM-3 ligands on NK cell function
by: Rieneke van de Ven
Published: (2025-07-01) -
Genetic Classification of Oral and Oropharyngeal Carcinomas Identifies Subgroups with a Different Prognosis
by: Serge J. Smeets, et al.
Published: (2009-01-01)